Related Experiment Video
Updated: May 30, 2026
05:18
Acupoint Catgut Embedding Therapy for Abdominal Obesity Treatment
Published on: November 22, 2024
Anticoagulating obese patients in the modern era
Jignesh P Patel1, Lara N Roberts, Roopen Arya
1King's Thrombosis Centre, Department of Haematological Medicine, King's College Hospital Foundation NHS Trust, London, UK. jig.patel@kcl.ac.uk
British Journal of Haematology
|August 19, 2011
Summary
Obesity increases anticoagulant clearance, complicating dosing. Pharmacokinetic-pharmacodynamic modeling is needed to establish safe and effective anticoagulant regimens for obese patients, addressing a critical clinical gap.
Area of Science:
- Pharmacology
- Clinical Medicine
- Obesity Research
Background:
- Rising obesity rates present challenges in anticoagulant therapy.
- Current anticoagulant dosing strategies for obese patients are not well-established.
- Increased anticoagulant clearance with higher body weight is suggested by existing research.
Purpose of the Study:
- To address the urgent need for evidence-based anticoagulant dosing in obese individuals.
- To guide clinicians in making informed anticoagulant decisions for patients with obesity.
- To establish appropriate anticoagulation regimens for the growing obese patient population.
Main Methods:
- Utilizing pharmacokinetic-pharmacodynamic (PK/PD) modeling.
- Employing simulation techniques to predict drug behavior.
- Analyzing existing research on anticoagulant clearance in relation to weight.
Main Results:
- Obesity is linked to increased anticoagulant clearance.
- Pharmacokinetic-pharmacodynamic modeling can provide a basis for dosing adjustments.
- Further research is required to confirm findings and guide clinical practice.
Conclusions:
- There is a significant need for optimized anticoagulant dosing in obese patients.
- Pharmacokinetic-pharmacodynamic modeling and simulation are crucial tools for developing evidence-based guidelines.
- Establishing clear anticoagulation regimens will improve patient safety and treatment efficacy.
Related Concept Videos
01:29Venous Thrombosis III: Interprofessional Care
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
01:21Drug Dosing: Obese Patients
In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
01:29Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care
Diagnosing Pulmonary EmbolismDiagnosing pulmonary embolism (PE) involves clinical assessment and advanced imaging tests. The preferred diagnostic tool is the spiral (helical) CT scan or CT angiography (CTA), which uses intravenous contrast media to visualize the pulmonary vasculature and identify emboli.A ventilation-perfusion (V/Q) scan is an alternative for patients unable to receive contrast media. This scan includes both perfusion and ventilation scanning. Perfusion scanning involves...
01:25Pharmacokinetics in Obese Patients: Drug Absorption and Distribution
Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...